Novartis India acquires Pfizer Minipress trademarks
Analysis based on 7 articles · First reported Sep 07, 2026 · Last updated Sep 07, 2026
The acquisition strengthens Novartis's cardiovascular portfolio and is expected to contribute incremental revenue, supporting its growth under new private-equity ownership. Pfizer's exit from the product in India reflects a strategic divestiture, with a one-time payment offsetting the discontinuation.
On September 7, 2026, Novartis announced the acquisition of the trademarks 'Minipress' and 'Minipres' registered in India, along with related intellectual property rights, from Pfizer and Pfizer — Pfizer Products Inc. for a total consideration of approximately ₹1,250 crore. The transaction was approved by Novartis's board and executed through an asset purchase agreement and trademark assignment deeds, with signing and closing occurring simultaneously. Minipress XL, containing prazosin, is used to treat hypertension and manage urinary symptoms of benign prostatic hyperplasia. According to IQVIA MAT July 2026 data, Minipress XL recorded revenue of ₹228.6 crore, growing at a CAGR of 6.3% over four years. Concurrently, Pfizer announced it would discontinue marketing, distribution, and sale of Minipress XL in India effective September 7, 2026, following Pfizer's decision to stop manufacturing the product. Pfizer will receive a lump-sum payment of $13.9 million (approximately ₹131.38 crore) from Pfizer USA. The acquisition follows ChrysCapital's acquisition of a 70.68% stake in Novartis from Novartis, and comes after Abbott Laboratories terminated its distribution agreement with Novartis for select brands, effective until September 30, 2026. Novartis shares rose 2.9% to ₹1,683.35 on the BSE, while Pfizer shares fell 0.8% to ₹4,572.70 on the NSE.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard